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Many pathogenic Gram-negative bacteria possess tri-
partite transporters that catalyze drug extrusion across
the inner and outer membranes, thereby conferring re-
sistance. These transporters consist of inner (IMP) and
outer (OMP) membrane proteins, which are coupled by
a periplasmic membrane fusion (MFP) protein. How-
ever, it is not know whether the MFP translocates the
drug between the membranes, by acting as a channel, or
whether it brings the IMP and OMP together, facilitat-
ing drug transfer. The MFP EmrA has an elongated
periplasmic domain, which binds transported drugs,
and is anchored to the inner membrane by a single -he-
lix, which contains a leucine zipper dimerization do-
main. Consistent with CD and hydrodynamic analyses,
the periplasmic domain is predicted to be composed of a
-sheet subdomain and an -helical coiled-coil. We pro-
pose that EmrA forms a trimer in which the coiled-coils
radiate across the periplasm, where they could seques-
ter the OMP TolC. The “free” leucine zipper in the EmrA
trimer might stabilize the interaction with the IMP
EmrB, which also possesses leucine zipper motifs in the
putative N- and C-terminal helices. The -sheet subdo-
main of EmrA would sit at the membrane surface adja-
cent to the EmrB, from which it receives the transported
drug, inducing a conformational change that triggers
the interaction with the OMP.
A major mechanism of resistance in pathogenic bacteria is
the extrusion of antibiotics from the cell. Gram-negative bac-
teria possess tripartite transport systems for translocating
drugs across both the inner membrane (IM)1 and the outer
membrane (OM). This system consists of inner and outer mem-
brane proteins, which translocate drugs across their respective
membranes but are coupled by a periplasmic protein (1). The
periplasmic domain of this protein is apparently anchored to
the IM via either a lipid moiety or an -helix. There has been
much speculation as to the functional role of this periplasmic
protein, the delineation of which is crucial to understanding
the mechanism of this type of transport system. One proposal is
that it forms a channel between the membranes; but another
suggests that it pulls the membranes together, allowing ligand
transfer between the IMP and OMP (2). Because of the latter
hypothesis this periplasmic protein was originally termed a
membrane fusion protein (MFP), but more recently the term
dynamic adaptor has been adopted (3).
The structures of two of the components of such a tripartite
complex, the OMP TolC (4) and the IMP AcrB (5), have recently
been determined by x-ray crystallography (4). Both TolC and
AcrB crystallize as trimers. The three TolC molecules are
structured into a 140-Å cylindrical channel with a 35-Å inter-
nal diameter. The OM end of the structure is open, providing
solvent access, but the periplasmic end tapers to a virtual close.
The structure can be divided into two major domains: an OM
-barrel and a periplasmic -helical barrel. The -barrel do-
main, which provides an essentially open channel through the
OM, is composed of 12 -strands, 4 donated by each TolC
molecule, arranged into a right-twisted barrel. The -helical
domain is a 12-helix barrel, constructed from long (67 residues)
and short (23 and 34 residues) helices, with pairs of the shorter
helices stacked to produce pseudo-continuous helices. The
-helices are further arranged into coiled-coils, and the mixed
/ structure connecting the shorter helices forms a belt
around the helical barrel. The -helical barrel is about 100 Å
long, which is close to the lower estimates of the depth of the
periplasmic space at 130 Å, but some estimates put the depth
of the periplasm at 250 Å and beyond the span of TolC (6, 7).
The AcrB trimer, which has a jellyfish-like appearance, com-
prises a periplasmic headpiece with dimensions of 50100 Å
and a transmembrane domain with dimensions of 70  80 Å
(5). The headpiece, which is formed by protrusions between
helices 1 and 2 and helices 7 and 8 of the transmembrane
domain, is divided into two stacked parts, with the upper and
lower parts 30 and 40 Å thick, respectively. Viewed from the
side, the upper part has a trapezoidal appearance, 70 Å wide at
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the bottom and 40 Å at the top; whereas viewed from above, the
upper part is open like a funnel, with an internal diameter of 30
Å. This funnel is connected by a pore, located between the
headpieces of the three protomers, to a large central cavity at
the interface of the headpiece and the transmembrane domains
of the protomers. The three transmembrane domains, each of
which is composed of 12 helices, are arranged into a ring with
a 30-Å hole between them, which might be filled with phospho-
lipids. It has been proposed that the upper headpiece interacts
with TolC (5), with six vertical hairpins from the AcrAB trimer
contacting the six -helix-turn--helix structures of the TolC
trimer, to form a continuous path across the periplasmic space.
If this is the case, it suggests a mechanism in which drugs
transported through the transmembrane domains of AcrB are
delivered to the central cavity created at the transmembrane
domain headpiece interface, where they can be shuttled
through the headpiece pore and funnel to TolC.
Interestingly, MFPs are predicted to have a structure that
resembles TolC; the N- and C termini of MFPs are proposed to
fold into a flattened -barrel, with the intervening residues
arranged into two long helices, each of about 60 or more resi-
dues, which fold back on one another to form a coiled-coil (2).
Considering those MFPs that utilize an N-terminal -helix to
anchor them to the IM, this would position the -barrel at the
IM with the -helices radiating out across the periplasm. Fur-
thermore, the ability of MFPs to form stable trimers (8, 9)
invites the suggestion that their role is to form a connecting
channel between the IM translocase and TolC. The putative
-barrel of the MFP could act as the receiver domain for drugs
released from the IM translocase, whereas the -helices could
transiently interact with TolC. A possible mechanism for this
interaction is that the six -helices of the MFP trimer form a
cylinder that inserts into the closed end of TolC to open it.
Considering however that both TolC and MFPs are highly
elongated molecules (4, 9) capable of overlapping in the
periplasmic space, a more likely mechanism is for the MFP to
utilize its -helices to “grab” the outer surface of TolC. There is
a deep cleft within the headpiece of AcrB in which the MFP
AcrA may lie, thereby positioning it to straddle both the
periplasmic domains of AcrB and TolC (5), and biochemical
cross-linking studies have revealed that the MFP-TolC inter-
action is substrate-induced and transient (8). On the other
hand, the -domain contains a motif that resembles the lipoyl
domain of enzymes involved in the transfer of a covalently
attached lipoyl or biotinyl moiety between proteins (2). In such
enzymes, this lipoyl domain is usually a flattened -barrel. The
formation of a similar domain would require the N- and C-
terminal domains of the MFP to interact, which might provide
a mechanism for bringing the two membranes together. How-
ever, the dimensions of AcrB and TolC are sufficient to indicate
that they can contact one another across the periplasm, argu-
ing against a role for the MFP in bringing the IM and OM
together.
This type of transport system is clearly of considerable sci-
entific and medical interest, because our knowledge of them is
rudimentary, and their study is likely to have medical benefits,
because they confer drug resistance and only effect transport in
bacteria. For this study, our aim was to characterize EmrA, the
MFP of a multidrug transporter from Escherichia coli (10), as a
structural and functional paradigm for the elucidation of the
properties of a number of IMP-MFP-OMP transport systems
and to address the central question of the role of the MFP in
drug translocation. The EmrAB transporter is composed of
EmrB, a putative 14-helix multidrug H antiporter belonging
to the major facilitator (MF) superfamily (11), and the MFP
EmrA. EmrA is predicted to have a short N-terminal cytoplas-
mic domain, a single transmembrane helix, and a large
periplasmic domain. The EmrAB proteins are thought to pro-
vide a continuous pathway across the bacterial membranes by
operating in conjunction with TolC (1). Underscoring the med-
ical importance of this system, homologues of EmrA and B have
been found in human pathogenic bacteria such as Vibrio chol-
erae (12), Neisseria gonorrhoeae (13), Strenotrophomonas mal-
tophilia (14), and Campylobacter jejuni (15). Also the genome
sequences of Bacillus subtilis, Haemophilus influenzae, Neis-
seria meningitidis, Bordatella pertussis, Rickettsia prowazeki,
and Yersinia pestis indicate that they possess related systems.
MATERIALS AND METHODS
Bacterial Strains and Plasmids—The pGEM-Teasy (Promega) plas-
mids bearing the emrA inserts were propagated in NovaBlue E. coli
cells (Novagen). The pET21 (Novagen) plasmid constructs bearing
emrA inserts were propagated in E. coli strain C41, a derivative of BL21
(16), and that bearing the hmrA insert was propagated in BL21* (In-
vitrogen). A acrA strain of E. coli, termed N43 (17), was transformed
with E. coli emrAB, NTemrAemrB (i.e. the construct expressed EmrA-
(49–390)), and H. influenzae hmrAB pUC constructs and used for
MIC measurements.
Overexpression and Purification of His-tagged EmrA Proteins—Chro-
mosomal DNA from E. coli strain DH5 was used as target DNA for
amplification of emrA by PCR using the forward and reverse oligonu-
cleotide primers 5-GGATCCAGCGCAAATGCGGAGACTCA-3 and 5-
CTCGAGGCCAGCGTTAGCTTTTACGAT-3, respectively. We incorpo-
rated BamHI and XhoI restriction sites (underlined) into these primers
to allow fragment ligation into pET21a to produce construct pET-EmrA-
(1–390). Four truncated fragments of EmrA were generated by PCR,
emrA-(15–390), emrA-(29–390), and emrA-(49–390), with the forward
primers 5-GGATCCAAGAGCGGCAAACGTAAG-3, 5-GGATCCC
TCTTTATAATTATTGCCGT-3 and 5-GGATCCGAAGAAACCGAT-
GACGCATACG-3, respectively, in combination with the reverse
primer used to clone emrA-(1–390), whereas emrA-(1–56) was gener-
ated with the forward primer used to clone emrA-(1–390) and the
reverse primer 5-CTCGAGCGTATGCGTCATCGGTTTCTTC-3. In
each case BamHI-XhoI restriction fragments were prepared and ligated
into pET21a to produce constructs pET-EmrA-(15–390), pET-EmrA-
(29–390), pET-EmrA-(49–390), and pET-EmrA-(1–56). Each pET con-
struct was sequenced to ensure its integrity and that it was in-frame
with the T7 and His6 tags.
The pET constructs were used to transform E. coli strain C41, pro-
viding expression of the His6-tagged proteins. A single colony of C41/
pET-EmrA was used to inoculate 5 ml of tryptone-yeast extract/50 g
ml1 carbenicillin (CB), grown to saturation at 37 °C, and used to
inoculate 0.5 liters of tryptone-yeast extract/50 g ml1 CB. Growth
was continued at 37 °C until reaching an A600 of 0.4–0.5, at which point
1 mM isopropyl-1-thio--D-galactopyranoside/50 g ml1 CB was added,
and the growth continued overnight at a reduced temperature of 23 °C.
For most preparations 3 liters of cells (e.g. 6  0.5 liters) were culti-
vated. Cells were harvested at 8670  g and washed with TNG buffer
(50 mM Tris-HCl (pH 8.5), 150 mM NaCl, 10% glycerol). The cell pellet
from each 0.5-liter culture was resuspended in 20 ml of TNG buffer,
giving 100 ml for a 3-liter culture, to which was added 0.5 ml 10 mg
ml1 lysozyme, 0.1 ml 10 mg ml1 DNase, and 1 protease inhibitor
mixture tablet (complete, EDTA-freeTM, Roche Molecular Biochemi-
cals). The cells were disrupted by passage through a cell disrupter
(model Z-plus 1.1 kilowatts, Constant Systems) operated at 4 °C. Un-
broken cells and cell debris were cleared from the supernatant at
39,000  g (20 min, 4 °C), which was then spun at 194,000  g (1.5 h,
4 °C), separating the soluble protein from the cell membrane pellet.
EmrA-(49–390) was isolated from the supernatant, EmrA-(1–56),
EmrA-(15–390), and EmrA-(1–390) from the membranes, and EmrA-
(29–390) from both the membrane and soluble fractions. For purifica-
tion of EmrA-(49–390), 6 ml of suspended Ni2-NTA-agarose (Qiagen)
was added to one-quarter of the supernatant and incubated for 1 h at
4 °C. A 1.5-cm-diameter Econo-columnTM (BioRad) was packed with the
Ni2-NTA-agarose to a final column volume of about 3 ml and washed
successively with 10, 2.5, and 0.5 volumes of TNG buffer containing 10,
25, and 50 mM imidazole, respectively, before elution of the protein
under gravity with 400 mM imidazole in 50 mM Tris-HCl (pH 8.5), 200
mM KCl (TK). Generally, 5 ml of protein at 15–20 mg ml1 was eluted
from the column, and then a further 5 ml of protein at 5 mg ml1 was
eluted, thus giving a yield of about 400 mg of protein from a 3-liter
culture. The protein was dialyzed against TK to remove the imidazole.
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EmrA-(29–390) was obtained from the soluble fraction in an identical
manner. For EmrA-(1–390), EmrA-(1–56), EmrA-(15–390), and EmrA-
(29–390) (membrane fraction) purifications, each membrane pellet was
solubilized by the addition of 1 volume of 1.5% dodecyl--D-maltoside in
TKG buffer (TK plus 10% glycerol) and incubated on ice for 1 h, after
which time 9 volumes of TKG was added to reduce the dodecyl--D-
maltoside concentration to 0.15%, and solubilized proteins were sepa-
rated from the membrane debris at 194,000  g. To 100 ml of super-
natant, 4 ml of suspended Ni2-NTA-agarose/1 protease inhibitor tablet
was added and incubated for 3 h at 4 °C. A 1-cm-diameter Econo-
column was packed with the Ni2-NTA-agarose to a final volume of
about 2 ml and washed successively with 10, 2.5, and 2 volumes of
TKGN (TKG plus 0.2% n-nonyl--D-maltoside) containing 10, 25, and
50 mM imidazole, respectively. 400 mM imidazole/TKGN was used to
elute the protein under gravity, with the protein usually occurring in
the second and third 1-ml aliquot at a concentration of 0.5–1 mg ml1.
The protein was dialyzed against TKGN to remove the imidazole.
Each pET-EmrA construct was tested for expression in the cyto-
plasm, inner membrane, and periplasm by purification. Proteins were
released from the periplasm by cold osmotic shock of the cells (18), and
the protein extract was treated according to the procedure adopted for
the purification of soluble EmrA proteins but maintaining the proteins
in glycerol-containing buffers. Proteins were quickly frozen and stored
at 80 °C.
Overexpression and Purification of the His-tagged HmrA
Protein—H. influenzae Rd, KW20, genomic DNA was obtained from the
American Type Culture Collection and used to PCR clone the periplas-
mic domain of HmrA, the H. influenzae homologue of EmrA, with the
primers 5-CACCATGTTTGAAGAAACAGAAGATGCTTATGTGG-3
and 5-ATGGCTGTTTTGCTGAATGATAGATTC-3. The resulting
product was cloned into the pET101/D-TOPO (Invitrogen) expression
vector giving the pHmrA-6H plasmid, which was used to transform E.
coli TOP10 cells, for overexpression of HmrA-(48–390). Automated
DNA sequencing of the plasmid confirmed the sequence and translation
frame as correct. pHmrA-6H was used to transform E. coli BL21*
(Invitrogen), which was used for all subsequent protein production.
BL21*/pHmrA-6H cells were grown at 37 °C in a 10-ml LB starter
culture containing 100 g/ml carbenicillin from a single colony picked
from a fresh agar plate. When the cells were just visible, 1 ml of starter
culture was used to inoculate 1 liter of LB containing 100 g/ml CB,
which was grown to an A600 of 0.4 at 37 °C with shaking at 200 rpm.
Cells were induced with 1 mM isopropyl-1-thio--D-galactopyranoside
for 3 h at 25 °C and then chilled on ice for 1 h. The cells were harvested
by centrifugation, resuspended in 50 mM HEPES (pH 8.0), 300 mM KCl,
and disrupted with a Cell Disrupter (Constant Systems). The cell debris
was removed by centrifugation and frozen in five 25-ml aliquots at
80 °C. HmrA-(48–390) was purified according to the same protocol
adopted for EmrA-(49–390).
Construction of pUC-EmrAB, pUC-EmrA-(49–390)B and pUC-HmrAB—
The emrA and emrB genes were amplified by PCR using the forward and
reverse primers 5-GAATTCGAGCGCAAATGCGGAGACTC-3 and 5-
GAAGCTTAGTGCGCACCTCCGCC-3, respectively, to introduce EcoRI
and HindIII sites (underlined) at the 5 and 3 ends of the amplified DNA,
which was purified and ligated into pGEMT-Easy (Promega). The emrAB
genes were rescued from pGEM-Teasy by restriction digest with EcoRI and
HindIII, ligated into EcoRI/HindIII-digested pUC to create pUC-EmrAB,
and transformed into E. coli strain N43. Similarly, the pUC-EmrA-(49–
390)B construct was made using the forward primer 5-GAATTCGAA-
GAAACCGATGACGCATACG-3, so that the expressed EmrA lacked the
first 48 amino acids. The constructs were checked by automated DNA
sequencing. The hmrA and hmrB genes were amplified by PCR using the
forward and reverse primers 5-GAATTCTGACGCAAATTGCAACT-3 and
5-GAAGCTTAATGCTGAGTACC AAA-3, respectively. The PCR product
was purified and ligated into pGEM-Teasy (Promega). The hmrAB genes
were rescued from pGEM-Teasy by restriction digest with EcoRI, ligated
into EcoRI-digested, alkaline phosphatase-treated pUC to create pUC-Hm-
rAB, and transformed into E. coli (NovoBlue, Invitrogen). Automated DNA
sequencing was used to identify a plasmid in which the hmrAB genes were
correctly orientated, which was then used to transform strain N43.
MIC Measurements—MICs were measured according to the microdi-
lution broth method established by the National Committee for Clinical
Laboratory Standards (19). Briefly, a single colony was picked from an
LB/ampicillin plate, used to inoculate 20 ml LB/ampicillin medium, and
grown to an A600 of 0.1. Cells were transferred to a microtiter plate and
mixed with serial dilutions of the drug to be tested. Bacterial growth
was monitored after an 18-h incubation at 37 °C.
Protein Concentration and Gel Analysis—Protein concentrations
were determined by the BCA assay using a kit from Pierce with bovine
serum albumin as standard. Proteins were separated by SDS-PAGE on
4–12% or 12% polyacrylamide gradient gels (NuPAGE gels and MES or
MOPS buffer; Novex) and stained with Coomassie Gelcode BlueTM
(Pierce). Protein samples for SDS-PAGE were mixed with the loading
buffer at room temperature to avoid any potential problems due to
protein aggregation, which can occur when samples are boiled. Native
PAGE (7.5% (BioRad) polyacrylamide gels and Tris-glycine buffer (pH
7.5) run for 16 h at 50 v) was also used to separate proteins.
Gel Chromatography—EmrA proteins were subjected to gel chroma-
tography on a Superdex 200 column run on an AKTA purifier (Amer-
sham Biosciences) automated chromatography system. EmrA-(1–390)
(1.3 mg ml1 in TKGN) and EmrA-(49–390) (3.0 mg ml1 in TKG) were
applied to a Superdex 200 HR 10/30 column equilibrated with PNGL
buffer (25 mM sodium phosphate (pH 8.0), 150 mM NaCl, 10% glycerol,
0.1% lauryldimethylamine-N-oxide) and eluted at a flow rate of 0.25 ml
min1. It was necessary to utilize PNGL as the equilibration buffer
because the separation of the monomers and dimers of EmrA was
inefficient when TKGN was used as the equilibration buffer, which
however is better for storage of EmrA. Although the retention time for
the EmrA-(49–390) monomer appeared to be less than for the EmrA-
(1–390) dimer and monomer, possibly because the proteins adopt dif-
ferent conformations, the column resolution would be relatively poor in
this range (e.g. between 45 and 90 kDa), and consequently there would
be difficulties in comparing the elution profiles from different runs.
Accordingly, we did not try to estimate the molecular masses of the
proteins from the retention times. Moreover, the proteins are likely to
elute as protein-detergent micelles with a greater molecular mass than
the protein.
Western Blotting and N-terminal Sequencing—EmrA-(1–390) mono-
mers and dimers were separated by gel chromatography on a Superdex
200 column, resolved by 12% SDS-PAGE, transferred to polyvinylidene
difluoride membrane and either immunoblotted with monoclonal anti-
polyhistidine antibodies (Sigma) or N-terminal sequenced (Alta Bio-
science, University of Birmingham, UK). The predicted amino acid
sequence of the EmrA-(2–390)-(His)6 fusion protein (i.e. termed EmrA-
(1–390)) was MASMTGGQQMGRDP-EmrA-(2–390)-LEHHHHHH,
with residues 2–12 constituting an immunogenic T7 tag. N-terminal
sequencing of the EmrA-(1–390) gave the first 11 and 10 residues of the
T7 tag for the monomer and dimer, respectively.
Spectroscopic Analyses—CD spectra were recorded on a Jasco J600
spectrometer at 20 °C using protein samples dialyzed into 50 mM Tris-
acetic acid (pH 8.0), 200 mM NaF. The percentage of secondary struc-
ture was predicted from the CD spectra using the program SELCON
(20).
Fluorescence measurements were made in a Jasco FP750 fluorimeter
at 20 °C. Tryptophan fluorescence was excited at 292.5 nm, and the
emission wavelength was scanned between 300 and 400 nm. For titra-
tions of EmrA-(49–390), KI was added from a 5 M stock solution to 2 ml
of 1.25 M protein in 50 mM Tris-HCl (pH 8.5), 200 mM NaCl. For KI
titrations in the presence of drugs, the drug concentration was set to the
maximum possible (e.g. 39 M FCCP, 48 M CCCP, 19 M DNP, 20 M
nalidixic acid, and 53 M chloramphenicol) that would not reduce the
protein fluorescence by more than 50% because of its inner filter effect.
In the case of nalidixic acid, the pH of the protein solutions was tested
to ensure that the small volume of acid added had not perturbed the pH.
The protein fluorescence and KI concentration were corrected for the
dilution effect. HmrA-(48–390) was routinely used at a concentration of
6 M because this gave a fluorescence equivalent to 1.25 M EmrA-(49–
390), but using the proteins at equivalent concentrations did not affect
the titration curves. The FCCP titration curve for EmrA was fitted to an
equation with hyperbolic and linear functions by nonlinear regression
using the program SigmaPlot (Jandel Scientific): y A [(B [FCCP]/
Kd  [FCCP])  (C  [FCCP])], where A is the value of F0/F in the
absence of FCCP, B is the total decrease in the value of F0/F for
concentrations of FCCP that tend toward saturating the hyperbolic
component attributed to specific binding, Kd is the dissociation constant
for the specific EmrA-(49–390)-FCCP complex, and C is the slope of the
linear component attributed to nonspecific binding.
Analytical Ultracentrifugation—Sedimentation velocity and sedi-
mentation equilibrium measurements were made with an Optima XL-A
analytical Ultracentrifuge (Beckman). Sedimentation was performed at
45,000 rpm in double sector cells at 20 °C, and the data were analyzed
using DCDT software, version 1.12 (21). We measured the value of s
for different protein concentrations in the range of 0.5–1 mg/ml in 40
mM potassium phosphate (pH 8.0), 400 mM KCl and extrapolated the
data to zero protein concentration. Sedimentation equilibrium experi-
ments were performed at 15,000, 18,000 and 20,000 rpm at 20 °C, and
the data were analyzed using the manufacturer’s software (Microcal
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Origin, version 4.1). The partial specific volume, v˜, was calculated as
0.736 ml/g from the amino acid sequence of EmrA-(49–390) using
SEDNTERP software (22); this value was used in all calculations.
Dynamic Light Scattering—Dynamic light scattering experiments
were performed on a Dynapro 801 (Protein Solutions Inc.) instrument
at 20 °C. Samples were injected at a concentration of 1 mg ml1. Data
analysis was performed using the manufacturer’s software.
RESULTS
EmrA Has a Periplasmic Domain That Is Anchored to the
Membrane by a Single -Helical Domain—Residues 23–46 of
EmrA were predicted, using the program TMHMM (23), to
form an -helix that anchors the protein in the periplasm of
E. coli. However, this prediction for EmrA, or for any other
MFP, has not been tested experimentally. To map the domains
of EmrA, a number of emrA constructs were made in pET to
overexpress the whole and truncated portions of EmrA (Fig. 1)
with a His tag to aid in purification (Fig. 2A). To determine the
location of each protein, we attempted their purification from
the periplasm milieu, obtained by osmotic shock of the cells,
from the cytoplasmic milieu, obtained as the soluble fraction
after cell disruption, and from inner membranes, prepared by
detergent solubilization of membranes from disrupted cells.
The EmrA-(1–390), EmrA-(15–390), and EmrA-(1–59) proteins
were purified from cytoplasmic membranes, whereas EmrA-
(49–390) was purified as a soluble protein from the cytoplasm.
In contrast, EmrA-(29–390) was obtained from both mem-
branes (about two-thirds of the total protein) and the cytoplasm
(about one-third of the total protein). None of the proteins was
purified from the periplasmic milieu following osmotic shock.
We concluded that EmrA is anchored to the membrane by
residues 15–49.
EmrA Forms Dimers and Trimers—An analysis of the EmrA-
(1–390) protein by SDS-PAGE (4–12% polyacrylamide gel,
MES buffer) revealed two predominant bands, one migrating
close to the expected molecular mass of 45.1 kDa and the other
with an apparent molecular mass of about 60 kDa (Fig. 2A, lane
5). Similarly, two predominant bands were apparent for the
truncate EmrA-(15–390), but both bands ran slightly faster
than the corresponding bands for EmrA-(1–390) (Fig. 2, A, lane
4, and B). This suggested that the higher molecular mass bands
were dimers of EmrA that ran at a lower than expected molec-
ular mass, as is usually the case for membrane proteins. How-
ever, better resolution of the dimer molecular mass was ob-
tained under alternate SDS-PAGE conditions (12% gel, MOPS
buffer), indicating that the dimer has a molecular mass in
excess of 64 kDa (Fig. 2B, lane 2). It seems unlikely that these
high molecular mass bands are attributable to complexes with
other proteins, such as EmrB and TolC, because their intensity
is much greater than would be expected when considering the
wild-type levels of expression of these proteins. Moreover, al-
though EmrA does not possess any cysteine residues, the pu-
tative dimer could be dissociated upon treatment with 4 M
-mercaptoethanol, with only the 45-kDa band apparent after
treatment (Fig. 2B, lane 1). Dissociation of the dimer was
presumably due to solvent effects, because the concentration of
-mercaptoethanol required to destabilize the dimer (e.g.2 M)
was much greater than normally used to reduce disulfide
bridges (e.g. 0.1 M) and the dimer could also be dissociated with
4 M Me2SO (data not shown). In some preparations we noted
the presence of a third predominant band with a molecular
mass of 100 kDa, suggestive of a trimer. However, this band
was not present in all preparations, just in the most concen-
trated protein preparations, and it tended to disappear after
extensive dialysis. This suggested that the monomer, dimer,
and trimer are in a concentration-dependent equilibrium. To
investigate this possibility further, we introduced a second
elution step into the EmrA-(1–390) protein purification proce-
dure, eluting the protein from the nickel-agarose column first
with 250 and then 400 mM imidazole and analyzing the sam-
ples by SDS-PAGE before dialysis. Our rational was that the
trimer, which would have three Ni2-binding sites, would be
held more tightly by the nickel-agarose than the monomer
and dimer and would elute preferentially with 400 mM imid-
azole. Adopting this refined purification protocol; we found
that, following a 2-ml wash with 250 mM imidazole, the
eluted protein was most concentrated in the first 1-ml elution
with 400 mM imidazole. Although the trimer was clearly
apparent in this elution fraction (Fig. 2C, lane 2), the mono-
mer and dimers were also at a higher concentration than in
the preceding or subsequent fractions. As with the dimer, 4 M
-mercaptoethanol dissociated the trimer, with only the mon-
omer band apparent on SDS-PAGE (data not shown). To
assess the possibility that the oligomerization of EmrA was in
fact SDS-induced aggregation of the protein, we also ran the
EmrA-(1–390) protein on native PAGE (7.5% polyacrylamide
gels/Tris-glycine buffer (pH 7.5)), upon which at least three
bands were visible (Fig. 2D), indicating that the oligomeriza-
tion of EmrA-(1–390) is not an artifact of the SDS treatment.
As a further test for dimerization, EmrA-(1–390) was sub-
jected to gel chromatography, which yielded two protein elu-
tion peaks, indicative of the monomer and the dimer (Fig.
FIG. 1. Schematic diagram of EmrA
based upon the predicted secondary
structure and domain mapping ex-
periments. A, schematic model of the
EmrA secondary structure. The amino
acid sequence surrounding the N-termi-
nal -helix that anchors EmrA to the in-
ner membrane is shown, indicating the
positions of the truncated EmrA con-
structs (in B) used to map the EmrA do-
mains. Those residues belonging to a pu-
tative leucine zipper motif, which runs
through the -helix, are underlined and
italic. B, predicted topologies of the trun-
cated derivatives of EmrA constructed to
map the domains of EmrA. The -helices
and -sheet domains are shown as rectan-
gles and saw-tooth schematics, respec-
tively. The letters in the membrane-span-
ning helix represent the leucine zipper
motif; note that this is truncated in
EmrA-(29–390).
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2E). The two proteins separated by gel chromatography were
confirmed as the monomer and dimer by SDS-PAGE (Fig.
2G), and the dimer dissociated in the presence of 4 M -mer-
captoethanol (Fig. 2G, lane 6). Consistent with the identity of
each protein as T7-EmrA-(2–390)-His6, both the monomer
and dimer cross-reacted with anti-polyhistidine antibodies
(Fig. 2H), indicating that both proteins had a C-terminal His
tag, whereas N-terminal protein sequencing confirmed that
both proteins carried an N-terminal T7 tag. From these ex-
periments we concluded that EmrA-(1–390) forms dimers and
trimers.
The N Terminus of EmrA Contains a Leucine zipper Motif
That Is Important for Dimerization—In contrast to EmrA-(1–
390), soluble EmrA-(49–390) migrated as a single band with an
apparent molecular mass of 40 kDa, consistent with the calcu-
lated molecular mass of 39.6 kDa (Fig. 2A, lane 2). Further-
more, EmrA-(49–390) predominantly eluted as a single protein
peak from a gel chromatography column, consistent with its
monomeric form (Fig. 2F). The slight shoulders on either side
the central protein peak are probably attributable to small
amounts of the dimer and a lower molecular mass-contaminat-
ing protein, which can be detected on Coomassie-stained gels
generally overloaded with EmrA proteins. We note that the size
of the contaminating protein is dependent upon the EmrA
truncate that it accompanies, being larger for EmrA (1–390)
than EmrA-(49–390), suggesting that it is a product of proteo-
lytic degradation of EmrA. These findings are consistent with
the prediction that residues 23–46 form a membrane-spanning
-helix that anchors EmrA to the membrane. The finding that
EmrA-(1–56) was exclusively membrane-bound provides fur-
ther evidence to support our conclusion (Fig. 2A, lane 7). There
is a predominant band that migrates with an apparent molec-
ular mass of about 12 kDa, suggestive of an EmrA-(1–56) dimer
because the calculated molecular mass of the monomer is 8.8
kDa. This behavior suggested that EmrA-(1–56) contains a
dimerization domain and provided a plausible explanation for
the fact that the EmrA-(49–390) protein migrates as a single
band (Fig. 2A, lane 2), whereas two bands are clearly apparent
for EmrA-(1–390) (Fig. 2A, lane 5) and EmrA-(15–390) (Fig. 2A,
lane 4). Interestingly, we noted that the sequence for the N-
terminal -helix that anchors EmrA to the membrane contains
a consensus sequence for a leucine zipper (e.g. counting from
Leu23 there are Leu, Leu, Ala, and Leu residues positioned at
and 3 are the second 1-ml fraction after the column is eluted with 250
mM imidazole (lane 1), the first 1-ml fraction (lane 2), and the pooled
second to eighth 1-ml fractions (lane 3) , respectively, after elution with
400 mM imidazole. The trimer appears concentrated in the first 1-ml
fraction eluted with 400 mM imidazole. D, a native gel (7.5% polyacryl-
amide, Tris-glycine buffer (pH 7.5), run at 50 v for 16 h) establishing
that EmrA-(1–390) forms oligomers in the absence of SDS (e.g. putative
monomer, dimer, and trimer bands are indicated by arrows). E and F,
separation of EmrA monomers and dimers by gel chromatography. The
elution profiles for EmrA-(1–390) (E) and EmrA-(49–390) (F) eluted
from a Superdex 200 column indicate that whereas EmrA-(1–390) ex-
ists in both monomeric and dimeric forms, EmrA-(49–390) is predom-
inantly monomeric. G, SDS-PAGE (12% polyacrylamide gel, MOPS
buffer) analysis of protein samples eluted from the Superdex 200 col-
umn: EmrA-(49–390) protein eluting between 10.5 and 11.5 ml (lane 1);
EmrA-(1–390) protein prior to application to a Superdex 200 column
(lane 2); EmrA-(1–390) protein eluting between 11 and 12 ml, which
had been incubated with the gel buffer for 20 min at 20 °C (lane 4) and
75 °C (lane 5) and treated with 4 M -mercaptoethanol (lane 6); EmrA-
(1–390) protein eluting between 12.5 and 14 ml (lane 8) and the same
protein heated to 75 °C for 20 min in the presence of 4 M -mercapto-
ethanol (lane 7). H, Western blot, using anti-polyhistidine antibodies, of
the purified protein fractions from the Superdex 200 column: the puta-
tive EmrA-(1–390) monomer eluting between 12.5 and 15 ml before
(lane 1) and after (lane 2) treatment with 4 M -mercaptoethanol; and
the putative dimer, eluting between 10.5 and 12 ml, before (lane 3) and
after (lane 4) treatment with 4 M -mercaptoethanol.
FIG. 2. EmrA is anchored to the membrane by an N-terminal
-helix that contains a dimerization domain. A, SDS-PAGE (4–
12% polyacrylamide gel, MES buffer) analysis of the EmrA proteins:
EmrA-(49–390) (lane 2), EmrA-(29–390) (lane 3), EmrA-(15–390) (lane
4), EmrA-(1–390) (lanes 5), and EmrA-(1–56) (lane 7). EmrA-(29–390),
EmrA-(15–390), EmrA-(1–390), and EmrA-(1–56) were isolated from
membranes and EmrA-(49–390) from the cytoplasm, consistent with
residues 23–46 forming an -helical membrane anchor. EmrA-(15–
390), EmrA-(1–390), and EmrA-(1–56), but not EmrA-(49–390), are
shown as forming dimers, demonstrating that this -helix contains a
dimerization domain. Consistent with the presence of a functional
leucine zipper in EmrA, EmrA-(29–390), which lacks the first Leu of the
putative leucine zipper motif, was membrane-bound but failed to form
dimers. B, SDS-PAGE (12% polyacrylamide gel, MOPS buffer) analysis
of untreated EmrA-(1–390) (lane 2) and EmrA-(1–390) treated with 4 M
-mercaptoethanol (lane 1), establishing that the higher molecular
mass band is a dimer that dissociates when treated with 4 M -mercap-
toethanol. C, SDS-PAGE (12% polyacrylamide gel, MOPS buffer) anal-
ysis of EmrA-(1–390) eluted from a nickel-agarose column: lanes 1, 2,
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intervals of 1, 8, 15, and 22 residues, respectively), which could
lead to the formation of a coiled-coil. To test this hypothesis, we
truncated EmrA at position 29, to produce a protein that would
still retain most of the -helix and therefore would be expected
to be membrane-bound but would lack the first leucine of the
zipper motif, weakening the dimer interactions. Consistent
with our hypothesis, the EmrA-(29–390) protein was mono-
meric and predominantly membrane-bound, migrating as a
single band to a position similar to that of the smaller EmrA-
(49–390), presumably because EmrA-(29–390) is a membrane
protein (Fig. 2A, lane 2). We conclude that membrane associa-
tion alone is insufficient to drive dimerization and that the
EmrA-(29–390) construct lacks a functional dimerization
domain.
Characterization of the Periplasmic Domain of EmrA—We
used the secondary structure prediction program Jpred (24),
which indicated that the periplasmic domain of EmrA consists
of a large -helix, comprising residues 96–213, sandwiched by
-sheet structure at the N- and C termini; overall the periplas-
mic domain has a 37.5% -helix and a 23% -sheet structure.
To test this latter prediction, we determined the CD spectra for
the EmrA-(49–390) protein, which was predicted to have 31%
-helix and 20.1% -sheet (Fig. 3A). Considering the possible
errors in determining the protein concentration and their effect
upon the CD analysis, this analysis is consistent with the
secondary structure prediction from Jpred. We also analyzed
the sequence using the program COILS (25), which predicted
that residues 95–144 and 156–182 could form the two helices of
a coiled-coil. These helices are shorter than the helical region
predicted by Jpred because of the presence of proline residues
at positions 148 and 197, which are excluded from the helices
predicted by COILS. Furthermore, the MULTICOIL (26) pro-
gram predicted that these helices would form dimers and, with
a higher probability, trimers. Consistent with this prediction,
we found that under native PAGE conditions, a concentrated
sample of EmrA-(49–390) formed oligomers (data not shown),
indicating a propensity of the periplasmic domain to oli-
gomerize; but presumably these contacts are less stable than
those in EmrA-(1–390) because we do not see oligomers of
EmrA-(49–390) on SDS-PAGE unless the gel was severely
overloaded with the protein. Furthermore, the insertion of
cysteine residues at the N- and C-terminal ends of EmrA-
(49–390) stabilized the formation of dimers and trimers by
the periplasmic domain, which were readily identified by
SDS-PAGE.2
If EmrA-(49–390) has two distinct domains, an -helical
coiled-coil domain and a -sheet domain, the stability of these
domains might differ under progressively denaturing condi-
tions, such as increasing GdmCl concentrations. Consistent
with this prediction we found that the CD signal at 222 nm,
indicative of the -helical content of the protein, underwent a
sharp transition (e.g. midpoint  1.125 M) to a lower level
with increasing concentrations of GdmCl, probably because of
the highly cooperative unfolding of the -helical coiled-coil
(Fig. 3B). Moreover, analysis of the individual CD traces
using the secondary structure prediction program SELCON
indicated, in contrast to the -structure, a decrease in the
-helical content of the protein with an increasing GdmCl
concentration, consistent with the predicted two-domain
structure.
We decided to test whether EmrA might also be an elongated
molecule, consistent with the predicted structure of a -barrel
attached to a long -helical coiled-coil. Analytical ultracentrif-
ugation was used to analyze the protein shape. First, a sedi-
mentation equilibrium analysis was used to assess the oligo-
meric state of EmrA-(49–390). These measurements indicated
that the protein is monomeric, with an average molecular mass
of 41 kDa, which is consistent with the calculated value of 39.6
kDa. To assess the symmetry of EmrA-(49–390), we measured
the sedimentation coefficient (s20,w
0 ), which was found to be 2.19
S at 20 °C, yielding a value for the Stokes radius (Rs) of 4.30
nm. In contrast, if EmrA-(49–390) was a compact sphere, it
should have a radius of 2.3 nm. These sedimentation data thus
suggest that EmrA-(49–390) is a highly asymmetric protein. To
confirm this conclusion, we measured the diffusion coefficient
(D20,w), which can also be determined from boundary spreading
sedimentation velocity data or, more directly, by dynamic light
scattering. The dynamic light scattering experiments indicated2 M. I. Borges-Walmsley and A. R. Walmsley, unpublished data.
FIG. 3. CD spectral analysis of EmrA-(49–390) and HmrA-(48–
390). A, the CD spectra for EmrA-(49–390) predict a secondary struc-
tural content of 31% -helix and 20.1% -sheet, consistent with the
Jpred prediction of a periplasmic domain consisting of an -helical
coiled-coil domain (37.5%) and a -sheet domain (23%). The CD spectra
for EmrA-(49–390) in the presence of GdmCl indicate a loss of signal at
222 nm, suggesting that the unfolding of EmrA-(49–390) primarily
involves a loss of -helical content. In contrast, a SELCON analysis
indicated that the -sheet content increased to more than 30% in
GdmCl concentrations above 1.25 M, suggesting that the -sheet do-
main is more stable than the -helical coiled-coil. As indicated by the
comparable CD spectra, HmrA-(48–390) adopts a structure similar to
that of EmrA-(49–390). B, unfolding transition of EmrA. The sharp
transition is consistent with the highly cooperative unfolding of the
-helical coiled-coil domain.
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a value for D20,w (1 mg ml
1 protein) of 4.5  107 cm2 s1,
which compares with a value of 5.5  107 cm2 s1 from
boundary spreading sedimentation velocity data, and gave a
measure of the hydrodynamic radius (Rh) of the protein of 4.7
nm, which is highly comparable with the measured Rs value of
4.3 nm. Assuming EmrA-(49–390) is a prolate ellipsoid, it is
possible to calculate the axial ratio and estimate the protein
dimensions (Table I). EmrA-(49–390) is predicted to have di-
mensions of 27  2.3 nm (i.e. 270  23 Å) at 20 °C.
EmrA Is Required for Antibiotic Resistance—pUC constructs
were used to express EmrA-EmrB and EmrA-(49–390)-EmrA-
EmrB in the E. coli acr deletion strain, N43, which is highly
susceptible to a wide range of antibiotics (17). Although full-
length EmrA and -B were able to confer resistance to CCCP,
FCCP, DNP, and nalidixic acid but not erythromycin or chlor-
amphenicol, cells expressing EmrA-(49–390)-EmrA and EmrB
were as susceptible to these agents as control cells transformed
with pUC (Table II). Because the EmrA-(49–390)-EmrA would
not be targeted to the membrane, the data indicate that resist-
ance cannot be conferred solely by EmrB. We also tested the
homologous genes hmrA and hmrB from H. influenzae for their
ability to confer resistance to these agents. Although these
genes did not confer resistance to FCCP and CCCP, they were
able to confer resistance to erythromycin, indicating that the
Hmr transport system was functional in strain N43 (Table II).
In this respect, HmrAB is not unique, because expression of
VceAB from V. cholerae has been shown to confer resistance
to drugs, including CCCP, when expressed in a emrB strain
of E. coli (12). Furthermore, the operon encoding VceAB also
encodes the OMP VceC, but VceAB expression is sufficient to
complement the deoxycholate sensitivity of a tolC strain of
E. coli (12), indicating that these transporters can operate as
bi- and tripartite systems. Indeed, recent studies have shown
that the MexJK efflux pump of Pseudomonas aeruginosa does
not require the OMP OprM for efflux of the biocide triclosan,
but it is required for efflux of the antibiotics tetracycline and
erythromycin (27).
The Periplasmic Domain of EmrA Binds Transported
Drugs—A potential role for EmrA is in the binding of drugs
exiting EmrB for transfer to TolC. In this case it might be
possible to detect the binding of drugs by fluorescence spectros-
copy if any of the four tryptophan residues present in the
periplasmic domain were to change environment upon drug
binding. Unfortunately it is not possible to monitor the inter-
action of these drugs with EmrA directly from changes in the
tryptophan fluorescence because they all produce a significant
inner filter effect that obscures any change in tryptophan flu-
orescence. However, the exposure of the tryptophan residues of
a protein can be assessed by their accessibility to quenching by
potassium iodide (28). The binding of a drug to EmrA might be
detected as a change in the exposure of the tryptophan residues
resulting from a conformational change. Consequently, as an
alternative to direct measurements of drug induced changes in
the tryptophan fluorescence, we determined the exposure of the
tryptophan residues in the absence and presence of drugs. If
the protein is titrated with KI, monitoring the quench in fluo-
rescence, the data can be analyzed as a Stern-Volmer plot of
F0/F versus the KI concentration, where F0 and F are the
fluorescence of the protein in the absence and presence of KI,
respectively (29). A linear plot is indicative of a single class of
quenchable tryptophan, but a downwardly curved plot indi-
cates that there are tryptophan residues that differ in their
accessibility to KI (28). As shown in Fig. 4A, the Stern-Volmer
plot for the KI quenching of EmrA-(49–390) was convex to the
abscissa, indicating that the four tryptophan residues present
in EmrA-(49–390) differ in their accessibility to KI. Clearly, in
the presence of the transported drugs FCCP, CCCP, DNP, and
nalidixic acid, the exposure of the tryptophan residues was
reduced, indicating that the binding of these drugs caused a
conformational change in EmrA. In contrast, chloramphenicol,
which is not a substrate of the EmrAB transporter, did not
appreciably reduce the exposure of the tryptophan residues of
EmrA. Although it is unlikely that the nonspecific binding of
these drugs would cause a conformational change at the con-
centrations used, we sought to investigate this possibility using
HmrA. It is reasonable to conclude that the HmrA and -B
proteins do not interact with FCCP because they do not confer
resistance to this drug. However, although the Emr and Hmr
transporters differ in their drug specificity, HmrA has 46.2%
identity with EmrA, with three of the tryptophans conserved in
the two proteins, suggesting that they will adopt very similar
structures. Consistent with this prediction, EmrA and HmrA
have similar CD spectra (Fig. 3A). Accordingly, HmrA-(48–
390) was titrated with KI in the absence and presence of FCCP
as a control to test for the effects of the nonspecific binding of
FCCP. As shown in Fig. 4B, a significant difference in the value
of F0/F in the absence and presence of FCCP was apparent only
at the highest KI concentration, consistent with a small non-
specific binding effect. To test whether the HmrA was correctly
folded and capable of binding transported substrates, the pro-
tein was titrated in the presence of erythromycin and nalidixic
acid (Fig. 4C). Interestingly, we found that HmrA did not
behave in an identical manner to EmrA, in that these sub-
strates caused an increase in the F0/F ratio for HmrA, indica-
tive of an increase in the exposure of the tryptophans due to
binding of these substrates. It is possible that this difference
results from the binding of drugs in the vicinity of Trp76 of
EmrA that is not conserved in HmrA.
We used the difference in quenching with 1 M KI, in the
presence and absence of FCCP, to titrate EmrA-(49–390) with
FCCP (Fig. 5). For low concentrations of FCCP the value for
F0/F decreased in a hyperbolic manner, but as the concentra-
tion was increased F0/F continued to decrease in an apparently
linear manner. This behavior is consistent with the specific
binding of FCCP at low concentrations but with nonspecific
binding becoming apparent at higher concentrations. Accord-
ingly, we analyzed the titration curve by nonlinear regression
fitting to an equation incorporating hyperbolic and linear func-
tions; this fitting procedure indicated a maximal quench in the
fluorescence of 8.1 (	2.8) % and a Kd for the specific EmrA-
(49–390)-FCCP complex of 4.2 (	2.6) M. The EmrE-FCCP
complex has a similar Kd value of 3.0 M (30). In contrast, when
TABLE I
Hydrodynamic parameters for the periplasmic domain of EmrA (EmrA-(49–390))
The conformational parameters, calculated using the experimentally obtained molecular mass and partial specific volume (v˜), were: s20,w
0 ,
sedimentation coefficient; D20,w, diffusion coefficient; Rs, Stokes radius; f and f0, fractional coefficients of EmrA-(49–390) and a sphere with a
volume equal to EmrA-(49–390); a/b, the axial ratio, where a is the long semi-axis and b is the short semi-axis of a prolate ellipsoid.
Parameters
s20,w
0 Rs D20,w Rh f/f0 a/b 2a 2b
s  1013 nm 107  cm2 s1 nm nm nm
Value 2.19 (	0.05) 4.3 5.45 (	0.05) 4.7 1.86 11.6 27 2.3
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HmrA-(48–390) was titrated with FCCP, F0/F decreased in a
linear manner with increasing FCCP concentration. This be-
havior parallels that of EmrA-(49–390) at high FCCP concen-
trations and is consistent with the nonspecific binding of FCCP
by HmrA-(48–390) (Fig. 4C). A similar analysis yielded Kd
values of 1.2 (	1.1) M and 9.4 (	6.6) M for the binding of
CCCP and DNP, respectively, to EmrA (data not shown),3
indicative of a correlation between the affinity of EmrA for the
drug and the resistance afforded. For example, EmrA binds
CCCP with the highest affinity, and this drug is the best
substrate for the EmrAB transport system as judged by the
increase in the MIC upon expression of the transport system in
a acr background. We conclude from this analysis that EmrA
is a drug-binding protein and is likely to play a role in the direct
transfer of drugs from EmrB to TolC.
DISCUSSION
The aim of this study was to characterize EmrA, a membrane
fusion protein from a tripartite multidrug extrusion system. By
truncating the EmrA protein we were able to show that it is
anchored to the inner membrane by residues 1–59, consistent
with the proposal that residues 23–46 form a membrane-span-
ning -helix, whereas residues 47–390 are arranged into a
soluble periplasmic domain. Indeed, we found that EmrA-(15–
390) was membrane-bound, whereas EmrA-(49–390) was sol-
uble, indicating that residues 15–48, but not 1–15 or 49–390,
are necessary for membrane insertion. Furthermore, EmrA-
(29–390) is partially soluble, suggesting that the membrane-
spanning helix starts between positions 15 and 29. We predict
that the periplasmic domain of EmrA comprises a short -sheet
domain (residues 48–95), a large -helical domain that is ar-
3 The fluorescence changes associated with the specific binding of
nalidixic acid were too small to be distinguished reliably from those
associated with nonspecific binding.
TABLE II
The susceptibility of the acrA mutant N43 expressing EmrAB, EmrA-(49–390)-EmrB, and HmrAB to various drugs: MIC measurements
for the three N43 transformants
pUC pUC-EmrAB pUC-EmrA-(49–390)B pUC-HmrAB
g ml1 g ml1 g ml1 g ml1
FCCP 14.8 59.3 14.8 14.8
CCCP 1.9 31.3 1.9 3.9
DNP 11.5 23 11.5 11.5
Nalidixic acid 1.1 8.7 1.1 8.7
Erythromycin 2.3 1.2 1.2 18.4
Chloramphenicol 2.6 2.6 2.6 2.6
FIG. 4. The periplasmic domain of EmrA possesses a drug-
binding site. A, Stern-Volmer plots for EmrA-(49–390) in the ab-
sence (closed circles) of drugs and in the presence of 39 M FCCP
(open circles), 19 M DNP (closed inverted triangles), 48 M CCCP
(closed squares), 20 M nalidixic acid (open inverted triangles), and 53
M chloramphenicol (open squares). The difference in the titration
curves is indicative of drug binding, and the lower end points, ob-
tained in the presence of drugs, indicate a decrease in the exposure of
the tryptophan residues of EmrA-(49–390) upon binding the drug.
Note that chloramphenicol, which is not an Emr substrate, has little
effect on the KI titration curve, consistent with the other drugs
binding specifically. B, Stern-Volmer plots for EmrA-(49–390) (closed
and open circles) and HmrA-(48–390) (closed and open inverted tri-
angles) in the absence and presence of 39 M FCCP, respectively. C,
Stern-Volmer plots for HmrA-(48–390) alone (closed circles) and in
the presence of 19 M nalidixic acid (open circles) and 17 M eryth-
romycin (closed inverted triangles).
FIG. 5. Titration of the drug binding site of EmrA. The fluores-
cence intensity of EmrA-(49–390) (closed circles) and HmrA-(48–390)
(open triangles) was measured in the presence of the indicated concen-
trations of FCCP (to give F0) and after the addition of 1 M KI (to give F).
The curve through the EmrA-(49–390) data points is the best-fit ob-
tained by a nonlinear regression fit of the data to an equation with
hyperbolic and linear functions, indicating a maximal quench in the
fluorescence of 8.1 (	2.8)% and a Kd for the specific EmrA-(49–390)-
FCCP complex of 4.2 (	2.6) M. For HmrA-(48–390), F0/F decrease in a
linear manner, paralleling the behavior of EmrA-(49–390) at high
FCCP concentrations, which is indicative of nonspecific binding.
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ranged into a coiled-coil (residues 96–213), and a large -sheet
domain (residues 214–374) with a short C-terminal helix (res-
idues 375–387). This secondary structure prediction is reason-
ably consistent with a CD analysis of EmrA-(49–390). In com-
mon with the MFP AcrA (9) we found that the periplasmic
domain of EmrA is highly elongated, with predicted dimensions
of 27  2.3 nm. EmrA is predicted to have a stretch of 110
residues, with an -helix structure, which is arranged into a
coiled-coil. Assuming that there are 3.5 amino acids/helix turn,
with a pitch of 0.51 nm/turn, we would expect this domain to
have dimensions of 17  2 nm. Thus, both our CD and hydro-
dynamic data are reasonably consistent with the Jpred second-
ary structure prediction of a two-domain protein, e.g. a globular
domain with a largely -sheet structure capping an -helical
coiled-coil domain.
Herein we provide evidence that membrane-bound EmrA
forms dimers and trimers. What is the structural basis for the
oligomerization of EmrA? EmrA is predicted to have an -hel-
ical coiled-coil structure, which is a common motif in oligomeric
proteins; the MULTICOIL program predicts that the coiled-coil
domain will form dimers and trimers. Consistent with this
prediction, we found that the soluble periplasmic domain of
EmrA (e.g. EmrA-(49–390)) formed oligomers (at relatively
high protein concentrations), but the dimers formed by mem-
brane-bound whole EmrA (e.g. EmrA-(1–390)) were more sta-
ble. We note that both membrane-bound and soluble AcrA form
dimers and trimers (31). However, AcrA differs from EmrA in
that it uses a lipid moiety to anchor it to the inner membrane,
indicating that the oligomerization site for AcrA lies within the
periplasmic domain. Another MFP, HlyD, was also shown to
form trimers (8), suggesting that this is a common feature of
MFPs. It seems most likely that a leucine zipper motif that
runs through the N-terminal helix of EmrA acts as a dimeriza-
tion domain, which stabilizes dimers of EmrA-(1–390) relative
to those of EmrA-(49–390). Perhaps formation of the dimer
provides a scaffold for trimerization, which results from inter-
actions between the periplasmic domains of EmrA. In such a
trimer the third leucine zipper motif would be “free.” Thus, it is
of interest to note that both the putative N-terminal (e.g. Leu7,
Ile14, Leu21, Leu28, and Val35, which span putative helix 1
between residues 13 and 38) and C-terminal helices (e.g.
Leu473, Ile480, Ile487, and Leu494, which span putative helix 14
between residues 482 and 504) of EmrB contain leucine zipper
motifs, which might interact with the free leucine zipper of the
EmrA trimer to form a stable EmrA-EmrB complex. No leucine
zipper motifs spanning the other putative helices of EmrB are
apparent. Recent studies of HylD indicate that its cytosolic
domain mediates transduction of the substrate binding signal
to the periplasmic domain to trigger recruitment of TolC (32).
Thus, it is inviting to speculate that substrate binding to EmrB
triggers communication between EmrB and EmrA via the
leucine zippers, with signal propagation to the periplasmic
domain of EmrA.
EmrA and TolC are predicted to have similar tertiary and
quaternary structures, an elongated /-barrel that forms tri-
mers (33). This is suggestive of a related structure and function
for these proteins, possibly with both acting to channel drugs
across the periplasm. Indeed, the trimeric structure of EmrA is
suggestive of the formation of a six-helix barrel, which could
form a connecting channel with TolC. However, both TolC and
EmrA are predicted to be sufficiently long to span most, if not
all, of the periplasmic space, bringing into question how this
interaction might be achieved if only the ends of the helical
channels are involved. An alternative hypothesis might be one
in which each -helical coiled-coil of trimeric EmrA would act
like “arms to grab” TolC, inducing the periplasmic end of TolC
to adopt an open confirmation. Consistent with this hypothesis,
recent studies indicate that a ring of aspartate residues (34)
and an intramolecular salt bridge (35) at the periplasmic end of
TolC control the opening of the tunnel; their interaction with
the MFP could be used to control the opening of TolC. However,
there is evidence that the IMP and MFP, which are coupled,
can work independently of the OMP (12, 27). It is possible that
the MFP performs a role similar to that of TolC but channels
the drugs to the outer membrane. Thermodynamically, the
delivery of hydrophobic drugs to the outer membrane would
be favorable.
On the basis of the structure of the RND antiporter, AcrB, it
has been suggested that the MFP AcrA binds to a large cleft in
the periplasmic headpiece of AcrB (5). In this position it would
overlap the periplasmic domains of AcrB and TolC, where it
could play a role in recruiting TolC. If this is the case, it brings
into question the site of interaction of EmrA with EmrB, be-
cause EmrB is a major facilitator antiporter (1), which does not
possess large periplasmic domains between helices 1 and 2 and
helices 7 and 8. Perhaps the leucine zipper motif of EmrA is of
importance in the EmrA-EmrB interaction, because it is notice-
able that whereas EmrA is anchored by an -helix, AcrA is
anchored to the membrane by a lipid moiety. It has also been
suggested that drugs can bind to the headpiece of AcrB and be
channeled into the central pore region (5). The headpiece con-
tains vestibules that are open to the periplasm, which could be
used to channel drugs to the pore at the center of the headpiece.
Drugs delivered to the pore from the periplasm could then be
delivered to TolC. Recent studies have shown that swapping
the periplasmic domains of the two RND antiporters, AcrB and
AcrD, which differ in their drug specificity, results in a change
in the drug specificity of the chimeric proteins (36), thus pro-
viding evidence that the periplasmic domains of AcrB are in-
volved directly in drug binding. Herein we provide evidence
that EmrA binds transported drugs, and it is tempting to
speculate that EmrA may serve a similar role to that of the
periplasmic domains of RND antiporters in drug binding and
transfer to the OMP.
A plausible model for the structure and function of the
EmrB-EmrA-TolC tripartite transport system might be one in
which EmrB and EmrA form a stable complex, possibly via
their membrane-spanning leucine zipper motifs, positioning
the -sheet domain of EmrA above EmrB at the surface of the
membrane, with the -helices radiating out across the
periplasm in position to contact TolC when triggered by the
binding of drugs to the -sheet domain of EmrA. The -helical
coiled-coils of EmrA would grab TolC so as to position the
-helical barrel of TolC above the -sheet domain of EmrA. The
drug could then be released from the -sheet domain of EmrA,
allowing it to diffuse into the channel formed by the TolC
trimer. Although one can envisage the drug moving from a less
hydrophobic site on EmrA/EmrB to a more hydrophobic site on
TolC, it is puzzling as to how TolC rids itself of the drug.
Clearly a detailed understanding of the function of EmrA will
require knowledge of the three-dimensional structure, and to-
ward this end we have recently succeeded in crystallizing
EmrA.
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